Full-Time

Clinical Research Associate 2

SCRA I

Syneos Health

Syneos Health

10,001+ employees

Global provider of integrated clinical-to-commercial services

No salary listed

Remote in Australia

Remote

Remote within Australia; pre-approved

Bachelor's

Category
Biology & Biotech (1)

Get referred to Syneos Health

See people who can refer or advise you

Requirements
  • Bachelor’s degree or RN in a related field or equivalent combination of education, training and experience
  • Knowledge of Good Clinical Practice/ICH Guidelines and other applicable regulatory requirements
  • Must demonstrate good computer skills and be able to embrace new technologies
  • Excellent communication, presentation and interpersonal skills
  • Ability to manage required travel of up to 75% on a regular basis
  • US ONLY: As part of your employment with Syneos Health, you may be deployed to Sites that require certain medical and other personal information to gain facility access. Pursuant to our Employee Privacy Notice, Syneos Health can provide the Sites with the information necessary for you to gain such access. Further, a Site may ask you for additional information beyond that which Syneos Health has in its possession. You are required to comply with any such Site requests as a condition of your employment with Syneos Health. Please note that failure to provide requested information may result in a Site barring you from entry, which could put your ongoing employment at risk.
Responsibilities
  • Performs site qualification, site initiation, interim monitoring, site management activities and close-out visits (performed on-site or remotely) ensuring regulatory, ICH-GCP and/or Good Pharmacovigilance Practice (GPP) and protocol compliance. Uses judgment and experience to evaluate overall performance of site and site staff and to provide recommendations regarding site-specific actions; immediately communicates/escalates serious issues to the project team and develops action plans. Maintains a working knowledge of ICH/GCP Guidelines or other applicable guidance, relevant regulations, and company SOPs/processes.
  • Verifies the process of obtaining informed consent has been adequately performed and documented for each subject/patient, as required/appropriate. Demonstrates diligence in protecting the confidentiality of each subject/patient. Assesses factors that might affect subject/patient’s safety and clinical data integrity at an investigator/physician site such as protocol deviation/violations and pharmacovigilance issues.
  • Per the Clinical Monitoring/Site Management Plan (CMP/SMP): Assesses site processes. Conducts Source Document Review of appropriate site source documents and medical records. Verifies required clinical data entered in the case report form (CRF) is accurate and complete. Applies query resolution techniques remotely and on site, and provides guidance to site staff as necessary, driving query resolution to closure within agreed timelines. Utilizes available hardware and software to support the effective conduct of the clinical study data review and capture. Verifies site compliance with electronic data capture requirements.
  • May perform investigational product (IP) inventory, reconciliation and reviews storage and security. Verifies the IP has been dispensed and administered to subjects/patients according to the protocol. Verifies issues or risks associated with blinded or randomized information related to IP. Applies knowledge of GCP/local regulations and organizational procedures to ensure IP is appropriately (re)labelled, imported and released/returned.
  • Routinely reviews the Investigator Site File (ISF) for accuracy, timeliness and completeness. Reconciles contents of the ISF with the Trial Master File (TMF). Ensures the investigator/physician site is aware of the requirement of archiving essential documents in accordance with local guidelines and regulations.
  • Documents activities via confirmation letters, follow-up letters, trip reports, communication logs, and other required project documents as per SOPs and Clinical Monitoring Plan/Site Management Plan. Supports subject/patient recruitment, retention and awareness strategies. Enters data into tracking systems as required to track all observations, ongoing status and assigned action items to resolution.
  • For assigned activities, understands project scope, budgets, and timelines; manages site-level activities / communication to ensure project objectives, deliverables and timelines are met. Must be able to quickly adapt to changing priorities to achieve goals / targets.
  • May act as primary liaison with study site personnel, or in collaboration with Central Monitoring Associate. Ensures all assigned sites and project-specific site team members are trained and compliant with applicable requirements
  • Prepares for and attends Investigator Meetings and/or sponsor face to face meetings. Participates in global clinical monitoring/project staff meetings (inclusive of Sponsor representation, as applicable) and attends clinical training sessions according to the project specific requirements.
  • Provides guidance at the site and project level towards audit readiness standards and supports preparation for audit and required follow-up actions.
  • Maintains a working knowledge of ICH/GCP Guidelines or other applicable guidance, relevant regulations, and company SOPs/processes; completes assigned training as required. For Real World Late Phase, the CRA II will use the business card title of Site Management Associate II. Additional responsibilities include:Site support throughout the study lifecycle from site identification through close-out. Knowledge of local requirements for real world late phase study designs.Chart abstraction activities and data collection Collaboration with Sponsor affiliates, medical science liaisons and local country staff. The SMA II may be requested to train junior staff. Identify and communicate out of scope activities to Lead CRA/Project Manager. Proactively suggest potential sites based on local knowledge of treatment patterns, patient advocacy and Health Care Provider (HCP) associations.

Syneos Health provides end-to-end biopharmaceutical solutions across the clinical-to-commercial spectrum. It helps biopharma companies, healthcare organizations, and investors by offering specialized expertise, insights, and technology-enabled services to move therapies faster to patients. Its offerings include Kinetic, a modern omnichannel customer engagement platform that uses targeting and analytics to coordinate nationwide healthcare communications, and Syneos One, an asset development approach that aligns strategy and execution from early concept through commercialization. The company uses AI and advanced tech to improve performance and reduce risk in drug development and market delivery. Its goal is to be a trusted partner that accelerates therapy development and delivery by combining scientific know-how with integrated, data-driven services.

Company Size

10,001+

Company Stage

IPO

Headquarters

Morrisville, North Carolina

Founded

1985

Get referred to Syneos Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Helio Genomics chose Syneos on May 19 2026 to commercialize HelioLiver nationwide.
  • Syneos embedded KAI Conversations on April 30 2026 for AI-driven U.S. commercialization.
  • May 14 2026 partnerships with CausaLens and Sageforce expand AI commercial tooling rapidly.

What critics are saying

  • Kempen v. Syneos entered discovery after the March 31 2026 dismissal ruling.
  • Plaintiffs allege Syneos inflated backlog and book-to-bill from 2020 through 2022.
  • Private-equity owners can prioritize leverage and cost cuts over R&D reinvestment by 2027.

What makes Syneos Health unique

  • Syneos spans preclinical through commercialization with a 2026 lab-to-life service model.
  • Kinetic unifies proprietary and partner intelligence for field execution and commercial precision.
  • Greg Licholai’s June 1 2026 CMO appointment deepens drug-development credibility with biopharma clients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Employee Stock Purchase Plan

Flexible Work Hours

Paid Vacation

Paid Sick Leave

Remote Work Options

Company News

PR Newswire
May 19th, 2026
Helio Genomics partners with Syneos Health to accelerate adoption of AI-powered liver cancer blood test

Helio Genomics has partnered with Syneos Health to accelerate nationwide adoption of HelioLiver, an AI-powered blood test for early liver cancer detection. Syneos Health will deploy field engagement and educational initiatives to reach hepatologists and gastroenterologists managing high-risk populations across the United States. HelioLiver combines cell-free DNA methylation patterns, protein biomarkers and patient demographics using proprietary AI algorithms. In the CLiMB trial involving nearly 1,968 patients across 50 clinical sites, the test demonstrated four times greater sensitivity for Stage I liver cancer compared to ultrasound. The test is reimbursed by Medicare at $662. The partnership builds on Helio Genomics' recent collaboration with Quest Diagnostics, providing access to over 7,700 patient service centres nationwide. Liver cancer incidence rates have tripled in the US since 1980.

Wallowa.com
Apr 30th, 2026
KAI Conversations announces strategic partnership with Syneos Health to advance U.S. Pharmaceutical commercialization.

KAI Conversations announces strategic partnership with Syneos Health to advance U.S. Pharmaceutical commercialization. GlobeNewswire | Syneos Health, Inc. Today at 9:30am PDT LONDON, April 30, 2026 (GLOBE NEWSWIRE) - KAI Conversations, an AI-powered conversation intelligence platform purpose-built for the pharmaceutical industry, today announced a strategic partnership with Syneos Health(R), a leading fully integrated biopharmaceutical solutions organization, to bring AI-driven field insights to the U.S. biopharma market. Pharmaceutical companies invest an estimated 30-50% of revenue in field teams, yet the majority of HCP interactions fail to translate into meaningful impact. This collaboration is designed to address that gap by helping companies turn everyday field conversations into actionable insights, more effective engagement and stronger brand performance. Through this strategic partnership, Syneos Health will embed KAI's platform into its commercial solutions - among the broadest in the industry - further strengthening the Company's ability to optimize field execution, accelerate behavior change and translate data-driven signals into measurable performance gains. KAI's platform, used by 10 of the top 20 global pharmaceutical companies across 15 therapeutic areas and multiple continents, analyzes conversations between field teams and healthcare professionals (HCPs). The platform delivers coaching to individual sales representatives while generating aggregated brand and customer intelligence for commercial and medical leaders. "The U.S. market represents a critical opportunity for pharmaceutical innovation and commercialization," said David Williams, Founder and CEO of KAI Conversations. "Partnering with Syneos Health enables us to scale our conversation intelligence through a trusted commercialization leader - equipping field teams with contextual coaching and insights to drive HCP engagement and stronger brand outcomes." "For years, valuable field insights were effectively invisible, locked inside everyday HCP conversations," said Paul Mignon, Head of Deployment Solutions at Syneos Health. "With KAI, we're surfacing real-time signals so our expert teams can optimize what works, predict what matters and automate next-best actions - driving precision performance to accelerate launch, adoption and growth." Together KAI and Syneos Health are advancing pharmaceutical commercialization by aligning AI-powered insights with integrated strategy, commercial execution and performance optimization. About KAI Conversations KAI Conversations is the world's leading AI conversation intelligence platform purpose-built for the pharmaceutical industry. The platform reveals previously hidden human insights by analyzing conversations between pharmaceutical field teams and healthcare professionals. By providing actionable insights and coaching, KAI empowers individuals and central teams to drive more effective engagement, enhance commercial outcomes, and accelerate brand performance. For more information, visit kaiconversations.com. This is a paid placement. For further inquiries, please contact GlobeNewswire directly.

Fierce Biotech
Mar 19th, 2026
Syneos Health scoops up Chinese CRO to secure place in ‘rapidly growing market’

North Carolina-based contract research organization Syneos Health is making a play to capitalize on China’s rapidly ascendant biopharma industry. | North Carolina-based contract research organization Syneos Health is making a play to capitalize on China’s rapidly ascendant biopharma industry. Syneos has acquired Chinese CRO Bestudy to secure a foothold in the Asian nation.

PRWeek
May 7th, 2025
Imre hires Greg Voyles as chief growth officer

Voyles joins Imre from Syneos Health, where he served as VP of commercial solutions.

Healthcare Asia Magazine
Dec 2nd, 2024
Sunway Healthcare Group, Syneos Health to expand clinical trial expertise

Sunway Healthcare Group has partnered with Syneos Health to expand clinical trial capabilities across therapeutic areas in Malaysia.